These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29353505)

  • 1. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.
    Fountzilas E; Said R; Tsimberidou AM
    Expert Opin Investig Drugs; 2018 Feb; 27(2):155-162. PubMed ID: 29353505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs.
    Bunnik EM; Aarts N; van de Vathorst S
    Health Policy; 2018 Sep; 122(9):977-983. PubMed ID: 29935731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
    Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE
    Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical, legal, and ethical issues in expanded access to investigational drugs.
    Darrow JJ; Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2015 Jan; 372(3):279-86. PubMed ID: 25587952
    [No Abstract]   [Full Text] [Related]  

  • 8. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
    McKee AE; Markon AO; Chan-Tack KM; Lurie P
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
    Bunnik EM; Aarts N
    BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dilemmas in the compassionate supply of investigational cancer drugs.
    Lewis JR; Lipworth W; Kerridge I; Doran E
    Intern Med J; 2014 Sep; 44(9):841-5. PubMed ID: 25201421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early phase clinical trials in pediatric hematology and oncology.
    Corbacioglu S
    Klin Padiatr; 2012 Apr; 224(3):197-200. PubMed ID: 22511313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of 21st Century Cures Act Expanded Access Policies Requirements.
    Kang S; Chang S; Ross JS; Miller JE
    Clin Pharmacol Ther; 2021 Dec; 110(6):1579-1584. PubMed ID: 34431083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
    Ochs A
    Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
    [No Abstract]   [Full Text] [Related]  

  • 14. The Practice of Pharmaceutics and the Obligation to Expand Access to Investigational Drugs.
    Buckley M; O'neil C
    J Med Philos; 2020 Mar; 45(2):193-211. PubMed ID: 31885051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
    Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
    ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society.
    Chahal M
    J Med Ethics; 2010 Jun; 36(6):367-70. PubMed ID: 20511354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug development in paediatric oncology].
    Benninger-Döring G; Boos J
    Klin Padiatr; 2006; 218(3):152-6. PubMed ID: 16688671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials.
    Caplan AL; Teagarden JR; Kearns L; Bateman-House AS; Mitchell E; Arawi T; Upshur R; Singh I; Rozynska J; Cwik V; Gardner SL
    J Med Ethics; 2018 Nov; 44(11):761-767. PubMed ID: 29982174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Right to Try" Laws: The Gap between Experts and Advocates.
    Dresser R
    Hastings Cent Rep; 2015; 45(3):9-10. PubMed ID: 25944200
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs.
    Hata T; Nakamura K; Yonemori K; Noguchi E; Watanabe M; Sohn J; Lu YS; Yap YS; Tamura K; Fujiwara Y
    Clin Transl Sci; 2021 May; 14(3):1015-1025. PubMed ID: 33382914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.